MedTrace Logo

Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)

NCT02180204 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2015-09-23

No results posted yet for this study

Summary

This is a double-blind parallel arm randomized trial aimed to assess efficacy and safety of intravenous Tenecteplase compared to intravenous Alteplase in eligible patients who present with symptoms of acute ischemic stroke within 3 to 4.5 hours from onset.

Conditions

Interventions

DRUG

Tenecteplase

Tenecteplase 0.25 mg/kg IV - Maximum 25 mg

DRUG

Alteplase

Alteplase 0.9 mg/kg IV - Maximum: 90 mg

Sponsors & Collaborators

  • Reza Behrouz, DO

    lead OTHER

Principal Investigators

  • Reza Behrouz, DO · The Ohio State University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02180204 on ClinicalTrials.gov